Literature DB >> 11867114

Drug-induced systemic lupus erythematosus associated with etanercept therapy.

Najia Shakoor, Margaret Michalska, Charlotte A Harris, Joel A Block.   

Abstract

Specific antagonists of tumour necrosis factor (TNF)-alpha have rapidly gained popularity for the treatment of rheumatoid arthritis. The monoclonal antibody against TNF-alpha, infliximab, has been associated with induction of systemic lupus erythematosus (SLE); however, there have been no published reports of drug-induced SLE associated with the soluble TNF-alpha receptor etanercept. We describe four female patients who developed signs and symptoms of SLE during treatment with etanercept; in two SLE was unambiguous. On diagnosis of SLE, etanercept was discontinued and the SLE-related symptoms promptly resolved. Etanercept should be considered in the list of agents associated with drug-induced SLE.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11867114     DOI: 10.1016/S0140-6736(02)07714-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  88 in total

1.  Myeloid dendritic cells from B6.NZM Sle1/Sle2/Sle3 lupus-prone mice express an IFN signature that precedes disease onset.

Authors:  Uma Sriram; Linda Varghese; Heather L Bennett; Neelakshi R Jog; Debra K Shivers; Yue Ning; Edward M Behrens; Roberto Caricchio; Stefania Gallucci
Journal:  J Immunol       Date:  2012-06-01       Impact factor: 5.422

Review 2.  Adverse drug reactions: back to the future.

Authors:  Munir Pirmohamed; B Kevin Park
Journal:  Br J Clin Pharmacol       Date:  2003-05       Impact factor: 4.335

3.  Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases.

Authors:  B Fautrel; J Sibilia; X Mariette; B Combe
Journal:  Ann Rheum Dis       Date:  2004-06-07       Impact factor: 19.103

Review 4.  Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Authors:  K L Hyrich; A J Silman; K D Watson; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2004-07-08       Impact factor: 19.103

5.  What is Known About the Association of Antinuclear Antibodies Development During Treatment with TNF Blockers?

Authors:  Mark Lebwohl
Journal:  J Clin Aesthet Dermatol       Date:  2008-09

6.  A practical approach to screening psoriasis patients for therapy with biologic agents.

Authors: 
Journal:  J Clin Aesthet Dermatol       Date:  2008-09

7.  [Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area].

Authors:  J Braun; J Zochling; E Märker-Hermann; G Stucki; H Böhm; M Rudwaleit; H Zeidler; J Sieper
Journal:  Z Rheumatol       Date:  2006-12       Impact factor: 1.372

Review 8.  Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; M Dougados; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

9.  ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; R Burgos-Vargas; E Collantes; J C Davis; B Dijkmans; M Dougados; P Géher; R D Inman; M A Khan; T K Kvien; M Leirisalo-Repo; I Olivieri; K Pavelka; J Sieper; G Stucki; R D Sturrock; S van der Linden; D Wendling; H Böhm; B J van Royen; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

10.  MHC class II, tumour necrosis factor alpha, and lymphotoxin alpha gene haplotype associations with serological subsets of systemic lupus erythematosus.

Authors:  N J McHugh; P Owen; B Cox; J Dunphy; K Welsh
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.